Multiple RFLPs of human complement component nine (C9) detected by TaqI

Por Rogne, S., Mevåg, B., Gedde-Dahl, T., Myklebost, O.
Publicado em 1990

Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.

Por Forus, A, Høifødt, H K, Overli, G E, Myklebost, O, Fodstad, O
Publicado em 1999

Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor.

Por Herz, J, Hamann, U, Rogne, S, Myklebost, O, Gausepohl, H, Stanley, K K
Publicado em 1988

The human genes for complement components 6 (C6) and 9 (C9) are closely linked on chromosome 5.

Por Rogne, S, Myklebost, O, Olving, J H, Kyrkjebø, H T, Jonassen, R, Olaisen, B, Gedde-Dahl, T
Publicado em 1991

Low-density-lipoprotein receptors in different rabbit liver cells.

Por Nenseter, M S, Myklebost, O, Blomhoff, R, Drevon, C A, Nilsson, A, Norum, K R, Berg, T
Publicado em 1989

Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b

Por Engkvist, M. E., Stratford, E. W., Lorenz, S., Meza-Zepeda, L. A., Myklebost, O., Munthe, E.
Publicado no Sci Rep (2017)

Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.

Por Maelandsmo, G. M., Berner, J. M., Flørenes, V. A., Forus, A., Hovig, E., Fodstad, O., Myklebost, O.
Publicado em 1995

Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas.

Por Forus, A., Berner, J. M., Meza-Zepeda, L. A., Saeter, G., Mischke, D., Fodstad, O., Myklebost, O.
Publicado em 1998

Interferon-γ suppresses S100A4 transcription independently of apoptosis or cell cycle arrest

Por Andersen, K, Smith-Sørensen, B, Pedersen, K B, Hovig, E, Myklebost, O, Fodstad, Ø, Mælandsmo, G M
Publicado em 2003

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes

Por Lauvrak, S U, Munthe, E, Kresse, S H, Stratford, E W, Namløs, H M, Meza-Zepeda, L A, Myklebost, O
Publicado em 2013

Patterns of genomic evolution in advanced melanoma

Por Birkeland, E., Zhang, S., Poduval, D., Geisler, J., Nakken, S., Vodak, D., Meza-Zepeda, L. A., Hovig, E., Myklebost, O., Knappskog, S., Lønning, P. E.
Publicado no Nat Commun (2018)

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival

Por Helland, Å., Brustugun, O. T., Nakken, S., Halvorsen, A. R., Dønnem, T., Bremnes, R., Busund, L. T., Sun, J., Lorenz, S., Solberg, S. K., Jørgensen, L. H., Vodak, D., Myklebost, O., Hovig, E., Meza‐Zepeda, L. A.
Publicado no Int J Cancer (2017)

Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization.

Por Armengol, G., Tarkkanen, M., Virolainen, M., Forus, A., Valle, J., Böhling, T., Asko-Seljavaara, S., Blomqvist, C., Elomaa, I., Karaharju, E., Kivioja, A. H., Siimes, M. A., Tukiainen, E., Caballín, M. R., Myklebost, O., Knuutila, S.
Publicado em 1997

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

Por Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Publicado no Blood Cancer J (2015)